Another major buy was in INTELLIA THERAPEUTICS INC (NASDAQ:NTLA), with ARK purchasing 191,705 shares for around $2.18 million through its ARKK ETF. Similar to CRISPR, INTELLIA has seen increased ...

The results suggest that lung xenotransplantation could one day become an option, but they also point to how much more work ...

Most Down syndrome research focuses on managing symptoms or treating associated health conditions rather than correcting the ...

There were more than 48,000 organ transplants in the U.S. in 2024, a 3.3% increase from 2023, according to Organ Procurement ...

Scientists have recently reported on the results of a universal cancer vaccine that boosts the immune system to fight tumors ...

The field of plant biotechnology is experiencing a revolution with the advent of advanced genome editing tools and ...

Research Topic Highlights<br/><br/>This collection highlights recent advances, potential, and challenges associated with emerging biotechnologies in agriculture, emphasizing the significant impact of ...

The ability to correct disease-causing genetic mistakes using genome editors holds great promise in medicine, but it is not without risk. When this type of “genetic surgery” is performed on DNA, for ...

Researchers demonstrate the active role methyl groups play in silencing genes, demonstrating the therapeutic potential of ...

RGA Investment Advisors, an investment management company, has released its second-quarter 2025 investor letter. A copy of ...

For years, researchers have been trying to figure out how to treat inherited blood disorders like sickle cell disease without ...

A new generation of CRISPR technology developed at UNSW Sydney offers a safer path to treating genetic diseases like Sickle Cell, while also proving beyond doubt that chemical tags on DNA - often ...